Best eMed Alternatives
eMed scores 66.5/100 in our independent evaluation, but it isn't the right fit for everyone. The most common reasons people look elsewhere: medication cost is separate and expensive: $550–$1,300/mo on top of $99/mo program fee; and very narrow scope — weight loss and urgent care only. Here are the 8 brands that compete with it most directly, ranked by category overlap and overall score.
Read our full eMed review for the complete score breakdown.
The largest publicly traded D2C telehealth platform, offering treatments across hair loss, ED, mental health, skincare, and weight loss.
- ▸Higher overall score (77.5/100 vs 66.5/100)
- ▸Better value score (70 vs 50)
- ▸Lower starting price ($11/mo vs $649/mo)
Vertically integrated private telehealth with in-house pharmacy, diagnostics, and an Eli Lilly partnership for branded GLP-1s.
- ▸Higher overall score (77/100 vs 66.5/100)
- ▸Stronger trust & safety score (85 vs 72)
- ▸Better value score (65 vs 50)
Prescription discount giant that expanded into telehealth, with the unique advantage of integrated drug price comparison.
- ▸Higher overall score (74.3/100 vs 66.5/100)
- ▸Better value score (85 vs 50)
- ▸Lower starting price ($16/mo vs $649/mo)
Pay-per-visit marketplace connecting patients with licensed providers — no subscriptions, transparent per-visit pricing.
- ▸Higher overall score (74/100 vs 66.5/100)
- ▸Better value score (80 vs 50)
- ▸Lower starting price ($34/mo vs $649/mo)
Cash-pay pharmacy and telehealth combo focused on transparent pricing and no-surprise billing.
- ▸Higher overall score (73.5/100 vs 66.5/100)
- ▸Better value score (82 vs 50)
- ▸Lower starting price ($179/mo vs $649/mo)
Direct-to-consumer telehealth platform selling compounded GLP-1 weight-loss medications and a compounded sublingual ED product, backed by a 40-year pharmacy partner.
- ▸Higher overall score (70.5/100 vs 66.5/100)
- ▸Better value score (74 vs 50)
- ▸Lower starting price ($114/mo vs $649/mo)
Fast-growing GLP-1 telehealth platform with flat dose-agnostic pricing and bundled labs; owner of Keeps, Nurx, and Cove via its $500M Thirty Madison acquisition.
- ▸Higher overall score (69/100 vs 66.5/100)
- ▸Better value score (80 vs 50)
- ▸Lower starting price ($189/mo vs $649/mo)
Publicly traded telehealth betting big on weight loss, with aggressive GLP-1 pricing and fast-growing subscriber base.
- ▸Higher overall score (68/100 vs 66.5/100)
- ▸Better value score (75 vs 50)
- ▸Lower starting price ($14/mo vs $649/mo)
Not sure which fits? Answer a few questions and we'll match you.
Take the Match Quiz